Your browser doesn't support javascript.
loading
A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
Tavenier, A H; Hermanides, R S; Ottervanger, J P; Rasoul, S; Slingerland, R J; Tolsma, R; van Workum, S; Kedhi, E; van 't Hof, A W J.
Afiliação
  • Tavenier AH; Department of Cardiology, Isala, Zwolle, The Netherlands.
  • Hermanides RS; Department of Cardiology, Isala, Zwolle, The Netherlands. r.s.hermanides@isala.nl.
  • Ottervanger JP; Department of Cardiology, Isala, Zwolle, The Netherlands.
  • Rasoul S; Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Slingerland RJ; Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands.
  • Tolsma R; Department of Clinical Chemistry, Isala, Zwolle, The Netherlands.
  • van Workum S; RAV IJsselland, Zwolle, The Netherlands.
  • Kedhi E; RAV Zuid-Limburg, Heerlen, The Netherlands.
  • van 't Hof AWJ; Department of Cardiology, Isala, Zwolle, The Netherlands.
Neth Heart J ; 27(4): 185-190, 2019 Apr.
Article em En | MEDLINE | ID: mdl-30767166
BACKGROUND: Fast and accurate platelet inhibition is an important therapeutic goal in the acute treatment of patients with ST-elevation myocardial infarction (STEMI). Platelet inhibitory effects induced by oral P2Y12-receptor antagonists are delayed in STEMI patients undergoing primary percutaneous coronary intervention (PCI) due to haemodynamic changes and delayed gastro-intestinal absorption. Concomitant use of opioids, although recommended in the American College of Cardiology/American Heart Association and European Society of Cardiology STEMI guidelines, further delays gastro-intestinal absorption. To date, trials investigating alternative analgesics in STEMI patients have been scarce. This trial aims to assess the feasibility of a novel drug strategy for treatment of STEMI patients with crushed ticagrelor in combination with paracetamol (acetaminophen) instead of opioids. HYPOTHESIS: STEMI patients who are pre-treated with crushed ticagrelor and paracetamol have a higher level of platelet inhibition after primary PCI than patients pre-treated with crushed ticagrelor and fentanyl. STUDY DESIGN: The Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial is a randomised controlled trial designed to examine whether administration of paracetamol instead of fentanyl can optimise platelet inhibition in STEMI patients who are pre-treated with crushed ticagrelor in the ambulance. One hundred and ninety patients with STEMI will be randomised (1:1 fashion) to intravenous (IV) fentanyl or IV paracetamol. The primary endpoint is the level of platelet reactivity units measured immediately after primary PCI. The ON-TIME 3 trial (NCT03400267) aims to achieve optimal platelet inhibition and pain relief in STEMI patients receiving crushed ticagrelor in the ambulance by investigating IV fentanyl and IV paracetamol as analgesics.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Ano de publicação: 2019 Tipo de documento: Article